EGFR T790M: revealing the secrets of a gatekeeper

Código QR

EGFR T790M: revealing the secrets of a gatekeeper

Brian Ko, Daniel Paucar, Balazs Halmos Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA Abstract: Non-small-cell lung cancers that harbor activating mutations in the EGFR gene represent an important molecularly defined subset...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ko B, Paucar D, Halmos B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	lung cancer epidermal growth factor receptor T790M targeted therapy resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3a360430f7c248bd9678fc8417144304
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
por: Klempner SJ, et al.
Publicado: (2017)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin E, et al.
Publicado: (2018)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation
por: Wang G, et al.
Publicado: (2019)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Yukari Tsubata, et al.
Publicado: (2021)

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
por: Tran PN, et al.
Publicado: (2016)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang Ying, et al.
Publicado: (2021)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
por: Junjie GU, et al.
Publicado: (2021)

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
por: Masatomo Ueda, et al.
Publicado: (2021)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts
por: Sreeranganathan M, et al.
Publicado: (2017)

ANALYSIS OF IMMUNOHISTOCHEMICAL EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN COLORECTAL CANCER
por: Ghazala Sadaf, et al.
Publicado: (2020)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios G, et al.
Publicado: (2021)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yaning Yang, et al.
Publicado: (2021)

Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
por: Dorjsuren B, et al.
Publicado: (2020)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel D, et al.
Publicado: (2021)

Targeting AXL in NSCLC
por: Zaman A, et al.
Publicado: (2021)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang W, et al.
Publicado: (2020)

Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
por: Dou XQ, et al.
Publicado: (2018)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Boning Cai, et al.
Publicado: (2021)

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami S, et al.
Publicado: (2017)

Surface Engineering of Escherichia coli–Derived OMVs as Promising Nano-Carriers to Target EGFR-Overexpressing Breast Cancer Cells
por: Zahra Sepahdar, et al.
Publicado: (2021)

Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
por: Stratmann JA, et al.
Publicado: (2019)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee CS, et al.
Publicado: (2020)

Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
por: Layla Al-mansoori, et al.
Publicado: (2021)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Xiaoying Zhang
Publicado: (2021)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
por: Cristina Minnelli, et al.
Publicado: (2021)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Yurong Wang, et al.
Publicado: (2021)

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
por: Dan Yan, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
por: Giacomo Aimar, et al.
Publicado: (2021)

Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
por: Anastasia V. Ignatova
Publicado: (2021)

EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles
por: Tsai WH, et al.
Publicado: (2018)

Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
por: Łukasz Trembecki, et al.
Publicado: (2021)

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
por: Legius B, et al.
Publicado: (2016)

Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer
por: Jin Zhou, et al.
Publicado: (2021)